CN118976023A - 治疗与s1p1受体有关的病况的方法 - Google Patents

治疗与s1p1受体有关的病况的方法 Download PDF

Info

Publication number
CN118976023A
CN118976023A CN202411067321.3A CN202411067321A CN118976023A CN 118976023 A CN118976023 A CN 118976023A CN 202411067321 A CN202411067321 A CN 202411067321A CN 118976023 A CN118976023 A CN 118976023A
Authority
CN
China
Prior art keywords
compound
subject
pharmaceutically acceptable
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411067321.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·纳伊克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN118976023A publication Critical patent/CN118976023A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN202411067321.3A 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法 Pending CN118976023A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
US62/789,937 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor
CN202080018255.4A CN113874009A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080018255.4A Division CN113874009A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Publications (1)

Publication Number Publication Date
CN118976023A true CN118976023A (zh) 2024-11-19

Family

ID=69467760

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411067321.3A Pending CN118976023A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法
CN202080018255.4A Pending CN113874009A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080018255.4A Pending CN113874009A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Country Status (10)

Country Link
US (1) US20220142977A1 (enExample)
EP (1) EP3908276B1 (enExample)
JP (1) JP2022516662A (enExample)
KR (1) KR20210113298A (enExample)
CN (2) CN118976023A (enExample)
AU (1) AU2020206700A1 (enExample)
CA (1) CA3124701A1 (enExample)
IL (1) IL284114A (enExample)
MX (1) MX2021008263A (enExample)
WO (1) WO2020146529A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
WO2020072824A1 (en) * 2018-10-03 2020-04-09 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma
WO2025177319A2 (en) * 2024-02-22 2025-08-28 Msn Laboratories Private Limited, R&D Center Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2326621T (pt) 2008-07-23 2016-09-12 Arena Pharm Inc Derivados de ácido 1,2,3,4-tetrahidrociclopenta[b]indol-3-il) acético substituídos úteis no tratamento de distúrbios autoimunes e inflamatórios
PT2342205T (pt) * 2008-08-27 2016-07-28 Arena Pharm Inc Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
US10040855B2 (en) * 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬

Also Published As

Publication number Publication date
WO2020146529A1 (en) 2020-07-16
CA3124701A1 (en) 2020-07-16
AU2020206700A1 (en) 2021-07-15
EP3908276A1 (en) 2021-11-17
IL284114A (en) 2021-08-31
US20220142977A1 (en) 2022-05-12
CN113874009A (zh) 2021-12-31
JP2022516662A (ja) 2022-03-01
KR20210113298A (ko) 2021-09-15
MX2021008263A (es) 2021-10-13
EP3908276B1 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
CN118976023A (zh) 治疗与s1p1受体有关的病况的方法
KR102824401B1 (ko) S1p1 수용체와 관련된 병태의 치료 방법
ES2987794T3 (es) Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
TWI322689B (en) Method for treating severe heart failure and medicament therefor
TWI646960B (zh) 慢性腎臟病之進展抑制或改善用製劑
CN119215038A (zh) mGluR5拮抗剂用于治疗阿片类物质镇痛耐受性的用途
WO2021163355A1 (en) Formulations and methods of treating conditions related to the s1p1 receptor
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
US20240238290A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
TW202222324A (zh) 克拉屈濱(Cladribine)用於治療免疫腦疾病的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116740

Country of ref document: HK